Literature DB >> 19300611

Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache.

Stefan Evers1.   

Abstract

Botulinum toxin A is increasingly used in the treatment of idiopathic and symptomatic headache disorders. However, only few controlled trials are available and many trials can hardly be compared to each other because of different endpoints and different trial designs. In particular chronic daily headache, which is defined as an idiopathic headache occurring on more than 15 days per month for at least 3 months and a daily duration of at least 4 hours, is considered as a headache disorder with possible efficacy of botulinum toxin A. For the prophylactic treatment of chronic tension-type headache and chronic migraine, no sufficient positive evidence for a successful treatment can be obtained from randomized, double-blind, and placebo-controlled trials to date. For the treatment of chronic daily headache including medication overuse headache, there is some positive evidence for efficacy in a subgroup of patients. To date, the majority of double-blind and placebo-controlled studies do not suggest that botulinum toxin A is efficacious in the treatment of chronic idiopathic headache disorders. However, it is possible that some subgroups of patients with chronic daily headache will benefit from a long-term treatment with botulinum toxin A.

Entities:  

Keywords:  botulinum toxin A; chronic daily headache; chronic migraine; chronic tension-type headache

Year:  2007        PMID: 19300611      PMCID: PMC2656318          DOI: 10.2147/ndt.s1665

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


  21 in total

1.  Guidelines for controlled trials of drugs in migraine: second edition.

Authors:  P Tfelt-Hansen; G Block; C Dahlöf; H C Diener; M D Ferrari; P J Goadsby; V Guidetti; B Jones; R B Lipton; H Massiou; C Meinert; G Sandrini; T Steiner; P B Winter
Journal:  Cephalalgia       Date:  2000-11       Impact factor: 6.292

Review 2.  Epidemiology of headache in Europe.

Authors:  L J Stovner; J-A Zwart; K Hagen; G M Terwindt; J Pascual
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

3.  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.

Authors: 
Journal:  Cephalalgia       Date:  1988       Impact factor: 6.292

Review 4.  Chronic daily headache.

Authors:  S D Silberstein; R B Lipton
Journal:  Curr Opin Neurol       Date:  2000-06       Impact factor: 5.710

5.  Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial.

Authors:  W J Schmitt; E Slowey; N Fravi; S Weber; J M Burgunder
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

6.  Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

7.  Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study.

Authors:  J D Rollnik; O Tanneberger; M Schubert; U Schneider; R Dengler
Journal:  Headache       Date:  2000-04       Impact factor: 5.887

Review 8.  Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside.

Authors:  David W Dodick
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

9.  Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial.

Authors:  M Padberg; S F T M de Bruijn; R J de Haan; D L J Tavy
Journal:  Cephalalgia       Date:  2004-08       Impact factor: 6.292

Review 10.  Botulinum toxin and the management of chronic headaches.

Authors:  Stefan Evers
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2004-06       Impact factor: 2.064

View more
  2 in total

Review 1.  Future drugs for migraine.

Authors:  Ivano Farinelli; Sergio De Filippis; Gabriella Coloprisco; Serena Missori; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2009-06-24       Impact factor: 3.397

2.  Botulinum toxin - From WMD to therapeutic agent and cosmetic aid.

Authors:  Roger M Pinder
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.